These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 33239000)

  • 21. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
    Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
    Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.
    Richeldi L; Crestani B; Azuma A; Kolb M; Selman M; Stansen W; Quaresma M; Stowasser S; Cottin V
    Respir Med; 2019 Sep; 156():20-25. PubMed ID: 31404749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
    Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
    Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
    Bonella F; Cottin V; Valenzuela C; Wijsenbeek M; Voss F; Rohr KB; Stowasser S; Maher TM
    Adv Ther; 2022 Jul; 39(7):3392-3402. PubMed ID: 35576048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
    Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subgroup analysis of Asian patients in the INPULSIS
    Taniguchi H; Xu Z; Azuma A; Inoue Y; Li H; Fujimoto T; Bailes Z; Schlenker-Herceg R; Kim DS
    Respirology; 2016 Nov; 21(8):1425-1430. PubMed ID: 27399197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
    Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
    Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
    Behr J; Kolb M; Song JW; Luppi F; Schinzel B; Stowasser S; Quaresma M; Martinez FJ
    Am J Respir Crit Care Med; 2019 Dec; 200(12):1505-1512. PubMed ID: 31365829
    [No Abstract]   [Full Text] [Related]  

  • 30. Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.
    Mira-Avendano I; Kaye M
    Ther Adv Respir Dis; 2024; 18():17534666241266343. PubMed ID: 39113425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.
    Kreuter M; Costabel U; Richeldi L; Cottin V; Wijsenbeek M; Bonella F; Bendstrup E; Maher TM; Wachtlin D; Stowasser S; Kolb M
    Respiration; 2018; 95(5):317-326. PubMed ID: 29414827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
    Lancaster L; Crestani B; Hernandez P; Inoue Y; Wachtlin D; Loaiza L; Quaresma M; Stowasser S; Richeldi L
    BMJ Open Respir Res; 2019; 6(1):e000397. PubMed ID: 31179001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
    Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
    Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
    Costabel U; Inoue Y; Richeldi L; Collard HR; Tschoepe I; Stowasser S; Azuma A
    Am J Respir Crit Care Med; 2016 Jan; 193(2):178-85. PubMed ID: 26393389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
    Yoon HY; Park S; Kim DS; Song JW
    Respir Res; 2018 Oct; 19(1):203. PubMed ID: 30340638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
    Keating GM
    Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.
    Kreuter M; Koegler H; Trampisch M; Geier S; Richeldi L
    Respir Res; 2019 Apr; 20(1):71. PubMed ID: 30971229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nintedanib for Idiopathic Pulmonary Fibrosis.
    Tepede A; Yogaratnam D
    J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
    Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
    Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.